Wednesday, March 12, 2014

The Motley Fool: Can Alexion Pharmaceuticals Continue to Deliver?

Successful biotechs are generally expected to reinvest their profits into the development of broad pipelines, but Alexion  (NASDAQ: ALXN  )  is following a somewhat different path. While I do not mean to give short shrift to this company's pipeline development efforts, the fact is that Alexion has been more interested in maximizing the value of its blockbuster orphan drug Soliris than relying on new development projects. That strategy has served the company well so far, and while there may some reasons to question whether health care systems will continue to support such generous reimbursement for orphan drugs, Soliris could yet offer significant growth potential.

Read more here:
Can Alexion Pharmaceuticals Continue to Deliver?

No comments: